Metastatic colorectal cancer cells maintain the TGFβ program and use TGFBI to fuel angiogenesis

Colorectal cancer (CRC) cells are traditionally considered unresponsive to TGFβ due to mutations in the receptors and/or downstream signaling molecules. TGFβ influences CRC cells only indirectly via stromal cells, such as cancer-associated fibroblasts. However, CRC cell ability to directly respond to TGFβ currently remains unexplored. This represents a missed opportunity for diagnostic and therapeutic interventions. Methods: We examined whether cancer cells from primary CRC and liver metastases respond to TGFβ by inducing TGFβ-induced protein ig-h3 (TGFBI) expression, and the contribution of canonical and non-canonical TGFβ signaling pathways to this effect. We then investigated in vitro and in vivo TGFBI impact on metastasis formation and angiogenesis. Using patient serum samples and an orthotopic mouse model of CRC liver metastases we assessed the diagnostic/tumor targeting value of novel antibodies against TGFBI. Results: Metastatic CRC cells, such as circulating tumor cells, directly respond to TGFβ. These cells were characterized by the absence of TGFβ receptor mutations and the frequent presence of p53 mutations. The pro-tumorigenic program orchestrated by TGFβ in CRC cells was mediated through TGFBI, the expression of which was positively regulated by non-canonical TGFβ signaling cascades. TGFBI inhibition was sufficient to significantly reduce liver metastasis formation in vivo. Moreover, TGFBI pro-tumorigenic function was linked to its ability to stimulate angiogenesis. TGFBI levels were higher in serum samples from untreated patients with CRC than in patients who were receiving chemotherapy. A radiolabeled anti-TGFBI antibody selectively targeted metastatic lesions in vivo, underscoring its diagnostic and therapeutic potential. Conclusions: TGFβ signaling in CRC cells directly contributes to their metastatic potential and stromal cell-independence. Proteins downstream of activated TGFβ, such as TGFBI, represent novel diagnostic and therapeutic targets for more specific anti-metastatic therapies.

[1]  Yili Yang,et al.  CCBE1 promotes tumor lymphangiogenesis and is negatively regulated by TGFβ signaling in colorectal cancer , 2020, Theranostics.

[2]  Pengfei Liu,et al.  Oncogenic MSH6-CXCR4-TGFB1 Feedback Loop: A Novel Therapeutic Target of Photothermal Therapy in Glioblastoma Multiforme , 2019, Theranostics.

[3]  Xu-Qiao Chen,et al.  The Role of TGF-β and Its Receptors in Gastrointestinal Cancers , 2019, Translational oncology.

[4]  J. Engstrand,et al.  Colorectal cancer liver metastases – a population-based study on incidence, management and survival , 2018, BMC Cancer.

[5]  M. Schwaiger,et al.  Exploring the Role of RGD-Recognizing Integrins in Cancer , 2017, Cancers.

[6]  G. Taylor,et al.  Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture , 2016, Gut.

[7]  F. Bertucci,et al.  Autocrine Secretion of Progastrin Promotes the Survival and Self-Renewal of Colon Cancer Stem-like Cells. , 2016, Cancer research.

[8]  J. Massagué,et al.  Metastatic colonization by circulating tumour cells , 2016, Nature.

[9]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[10]  M. Ekstedt,et al.  A Novel SMAD4 Mutation Causing Severe Juvenile Polyposis Syndrome with Protein Losing Enteropathy, Immunodeficiency, and Hereditary Haemorrhagic Telangiectasia , 2015, Case reports in gastrointestinal medicine.

[11]  P. Bragado,et al.  Mechanisms of disseminated cancer cell dormancy: an awakening field , 2014, Nature Reviews Cancer.

[12]  P. Delvenne,et al.  Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies , 2014, Hepatology.

[13]  P. ten Dijke,et al.  Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. , 2013, Trends in biochemical sciences.

[14]  Eugene A. Kapp,et al.  Colon tumour secretopeptidome: insights into endogenous proteolytic cleavage events in the colon tumour microenvironment. , 2013, Biochimica et biophysica acta.

[15]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[16]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[17]  S. Mohan,et al.  Targeted Disruption of TGFBI in Mice Reveals Its Role in Regulating Bone Mass and Bone Size through Periosteal Bone Formation , 2012, Calcified Tissue International.

[18]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[19]  I. Cuthill,et al.  Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .

[20]  P. Jurek,et al.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.

[21]  Shibo Jiang,et al.  Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. , 2008, Genes & development.

[22]  S. Dupont,et al.  Links between Tumor Suppressors p53 Is Required for TGF-β Gene Responses by Cooperating with Smads , 2003, Cell.

[23]  D. Felsen,et al.  Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: implications for fibrosis in kidney disease. , 2001, The American journal of pathology.

[24]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[25]  W. Bodmer,et al.  Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Castronovo,et al.  Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. , 1998, Journal of the National Cancer Institute.

[27]  H. Beug,et al.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.

[28]  O. Huber,et al.  Algal‐CAMs: isoforms of a cell adhesion molecule in embryos of the alga Volvox with homology to Drosophila fasciclin I. , 1994, The EMBO journal.

[29]  A. Turtoi,et al.  Paracrine interactions of cancer-associated fibroblasts, macrophages and endothelial cells: tumor allies and foes , 2018, Current opinion in oncology.

[30]  G. Bhagat,et al.  TGFBI deficiency predisposes mice to spontaneous tumor development. , 2009, Cancer research.

[31]  Boris Pasche,et al.  TGF-beta signaling alterations and susceptibility to colorectal cancer. , 2007, Human molecular genetics.

[32]  J. Jass,et al.  Microsatellite unstable colorectal cancer cell lines with truncating TGFbetaRII mutations remain sensitive to endogenous TGFbeta. , 2007, The Journal of pathology.

[33]  J. Price,et al.  Organ distribution of experimental metastases of a human colorectal carcinoma injected in nude mice , 2005, Clinical & Experimental Metastasis.

[34]  K. Kinzler,et al.  Secreted and cell surface genes expressed in benign and malignant colorectal tumors. , 2001, Cancer research.

[35]  L. Madisen,et al.  cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. , 1992, DNA and cell biology.